期刊
CANCER LETTERS
卷 328, 期 2, 页码 307-317出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.10.001
关键词
ABC transporters; ABCB1/P-gp; ABCC10/MRP7; ABCG2/BCRP; Nilotinib; Multidrug resistance
类别
资金
- National Institutes of Health [1R15CA143701]
- St. John's University Seed Grant [579-1110]
A panel of clinically used tyrosine kinase inhibitors were compared and nilotinib was found to most potently sensitize specific anticancer agents by blocking the functions of ABCB1/P-glycoprotein, ABCG2/BCRP and ABCC10/MRP7 transporters involved in multi-drug resistance. Nilotinib appreciably enhanced the antitumor response of (1) paclitaxel in the ABCB1- and novel ABCC10-xenograft models, and (2) doxorubicin in a novel ABCG2-xenograft model. With no apparent toxicity observed in the above models, nilotinib attenuated tumor growth synergistically and increased paclitaxel concentrations in ABCB1-overexpressing tumors. The beneficial actions of nilotinib warrant consideration as viable combinations in the clinic with agents that suffer from MDR-mediated insensitivity. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据